FDA approves Tremfya for pediatric plaque psoriasis, active psoriatic arthritis
The U.S. Food and Drug Administration has approved Johnson & Johnson's Tremfya (guselkumab) for the treatment of plaque psoriasis and active psoriatic arthritis in children 6 years of age and older.
Oct 3, 2025
0
17









